Cargando…
Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers
OBJECTIVES: To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC). METHODS: This retrospective study was conducted on 823 DTC patients treated between 2...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Saudi Medical Journal
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404478/ https://www.ncbi.nlm.nih.gov/pubmed/25828281 http://dx.doi.org/10.15537/smj.2015.4.10341 |
_version_ | 1782367497175957504 |
---|---|
author | Al-Qahtani, Khalid H. Al-Asiri, Mushabbab Tunio, Mutahir A. Aljohani, Naji J. Bayoumi, Yasser Al-Hussain, Hussain Maklad, Ahmed M. |
author_facet | Al-Qahtani, Khalid H. Al-Asiri, Mushabbab Tunio, Mutahir A. Aljohani, Naji J. Bayoumi, Yasser Al-Hussain, Hussain Maklad, Ahmed M. |
author_sort | Al-Qahtani, Khalid H. |
collection | PubMed |
description | OBJECTIVES: To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC). METHODS: This retrospective study was conducted on 823 DTC patients treated between 2000 and 2012 at 2 tertiary care hospitals (King Fahad Medical City and King Khalid University Hospital) in Riyadh, Kingdom of Saudi Arabia. Forty-one (5%) DTC patients were found to have SPM (61% metachronous and 39% synchronous). These patients with SPM were studied for clinicopathological features and treatment outcomes. RESULTS: The patients with DTC and SPM were older (median age: 54.3 years) than those without SPM (median age: 43.2 years); p=0.04. The frequency of SPM was breast (51.2%), colon (12.2%), kidney (7.3%), astrocytoma (7.3%), parotid (7.3%), rectum (4.9%), lymphoma (4.9%), nasopharynx (2.4%), and stomach (2.4%). Median follow-up was 8.05 years. Ten-year disease free survival, and overall survival (OS) rates were lower in DTC patients with SPM (56.1% for 10-year survival, and 71.7% for OS) than without SPM (95.5% for 10-year survival, and 97.8% for OS); p=0.0001. Metachronous SPM had better 10-year disease free survival rates (60.2%) than synchronous SPM (45%). CONCLUSION: The co-occurrence of SPM with DTC affects long-term disease free survival and OS rates. |
format | Online Article Text |
id | pubmed-4404478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Saudi Medical Journal |
record_format | MEDLINE/PubMed |
spelling | pubmed-44044782015-04-28 Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers Al-Qahtani, Khalid H. Al-Asiri, Mushabbab Tunio, Mutahir A. Aljohani, Naji J. Bayoumi, Yasser Al-Hussain, Hussain Maklad, Ahmed M. Saudi Med J Original Article OBJECTIVES: To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC). METHODS: This retrospective study was conducted on 823 DTC patients treated between 2000 and 2012 at 2 tertiary care hospitals (King Fahad Medical City and King Khalid University Hospital) in Riyadh, Kingdom of Saudi Arabia. Forty-one (5%) DTC patients were found to have SPM (61% metachronous and 39% synchronous). These patients with SPM were studied for clinicopathological features and treatment outcomes. RESULTS: The patients with DTC and SPM were older (median age: 54.3 years) than those without SPM (median age: 43.2 years); p=0.04. The frequency of SPM was breast (51.2%), colon (12.2%), kidney (7.3%), astrocytoma (7.3%), parotid (7.3%), rectum (4.9%), lymphoma (4.9%), nasopharynx (2.4%), and stomach (2.4%). Median follow-up was 8.05 years. Ten-year disease free survival, and overall survival (OS) rates were lower in DTC patients with SPM (56.1% for 10-year survival, and 71.7% for OS) than without SPM (95.5% for 10-year survival, and 97.8% for OS); p=0.0001. Metachronous SPM had better 10-year disease free survival rates (60.2%) than synchronous SPM (45%). CONCLUSION: The co-occurrence of SPM with DTC affects long-term disease free survival and OS rates. Saudi Medical Journal 2015 /pmc/articles/PMC4404478/ /pubmed/25828281 http://dx.doi.org/10.15537/smj.2015.4.10341 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Al-Qahtani, Khalid H. Al-Asiri, Mushabbab Tunio, Mutahir A. Aljohani, Naji J. Bayoumi, Yasser Al-Hussain, Hussain Maklad, Ahmed M. Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers |
title | Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers |
title_full | Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers |
title_fullStr | Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers |
title_full_unstemmed | Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers |
title_short | Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers |
title_sort | prevalence and treatment outcomes of second primary malignancies in saudi patients with differentiated thyroid cancers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404478/ https://www.ncbi.nlm.nih.gov/pubmed/25828281 http://dx.doi.org/10.15537/smj.2015.4.10341 |
work_keys_str_mv | AT alqahtanikhalidh prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers AT alasirimushabbab prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers AT tuniomutahira prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers AT aljohaninajij prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers AT bayoumiyasser prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers AT alhussainhussain prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers AT makladahmedm prevalenceandtreatmentoutcomesofsecondprimarymalignanciesinsaudipatientswithdifferentiatedthyroidcancers |